Lexaria Bioscience: Improving Oral Weight-Loss Drug Tolerability
Next-generation weight-management drugs face a simple challenge: effectiveness must be matched by tolerability.
Delivery technology may be the missing piece in next-generation obesity therapies.
Lexaria Bioscience is advancing a patented oral delivery platform that improved tolerability in a clinical study by reducing adverse events by up to 50%, targeting a large and growing metabolic treatment market.
Next-generation weight-management drugs face a simple challenge: effectiveness must be matched by tolerability.
Lexaria Bioscience focuses on absorption — the step that determines how a drug behaves in the body.
Its delivery technology reduced adverse events by up to 50% in clinical testing, suggesting improved patient experience without altering the therapeutic compound itself.
Rather than developing a single medication, the company is positioning its platform as a potential enhancement layer for future oral therapies across multiple pharmaceutical categories.
To learn more about Lexaria Bioscience Corp. (NASDAQ: LEXX), watch their video HERE
Published by BTV - The Agency
Discover Investment Opportunities with BTV. Delivering engaging content to Investors for 25+ years.
.jpg)
You might also like
Critical Elements Lithium Poised to Support Growing Demand Beyond EVs
Critical Elements Lithium is ready to fuel tomorrow’s energy by advancing its Rose Lithium-Tantalum Project in Quebec. The company’s focus is on producing high-purity spodumene concentrate to supply the flourishing electric vehicle and energy storage systems industries.
Critical Elements Lithium: Is Quebec ready to deliver new North American supply?
Global lithium demand is expected to rise from roughly 1.2 million tonnes in 2025 to about 3 million tonnes by 2030, driven largely by electric vehicles and energy storage for ravenous data centres and artificial intelligence. Management believes supply will struggle to keep pace, creating room for new producers with near-term projects.
Harvest HPYB ETF Income From Canadian Banks
Harvest Premium Yield Canadian Bank ETF (HPYB) is built to generate higher income from Canadian bank stocks by combining bank exposure with an active options strategy that sells calls and puts, producing more tax-efficient cash flow than dividends alone.